Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | THPO | P40225 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GMNN | O75496 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335341 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| SCHEMBL4038832 | 0.94 | CYP3A4 (0.52) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| SCHEMBL6338922 | 0.94 | CYP3A4 (0.52) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| SCHEMBL4040369 | 0.93 | LMNA (0.48) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| Hydrochloric Acid SCHEMBL4036505 | 0.93 | LMNA (0.53) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| Hydrochloric Acid SCHEMBL4041643 | 0.92 | LMNA (0.49) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| SCHEMBL4039594 | 0.92 | MEN1 (0.39) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| Hydrochloric Acid SCHEMBL4037809 | 0.90 | KMT2A (0.40) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| SCHEMBL6333770 | 0.89 | KMT2A (0.39) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR | |
| SCHEMBL4041840 | 0.89 | SMN1; SMN2 (0.40) | CYP3A4CYP1A2CYP2D6CYP2C19MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284977-B1 | THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-24 | — | — | EP | claimed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | claimed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | claimed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | claimed |
| EP-1284977-B1 | THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-24 | — | — | EP | disclosed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | disclosed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | disclosed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | CYP3A4 1915/4885CYP1A2 924/4885CYP2D6 882/4885 |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | CYP3A4 1838/4885CYP1A2 863/4885CYP2D6 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.